Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This is a combination drug used for the treatment of functional dyspepsia and other digestive disorders. Mosapride is a selective 5-HT4 receptor agonist that promotes acetylcholine release, stimulating gastrointestinal motility and improving symptoms such as bloating, nausea, vomiting, early satiety, and abdominal discomfort[2][3][4]. Aspergillus oryzae pancreatin (米曲菌胰酶片) contains digestive enzymes including amylase, protease, lipase from Aspergillus oryzae and pancreatic enzymes; it aids in the digestion of carbohydrates, proteins, and fats in the stomach and intestines[1][7]. The combination is used to address both impaired gastrointestinal motility (via mosapride) and insufficient digestive enzyme activity (via Aspergillus oryzae pancreatin), providing comprehensive relief for patients with functional dyspepsia.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mosapride + aspergillus oryzae pancreatin.